Bioscience Company Secures $14 Million Grant For Clinical Development of Opioid Treatment
Innovative Approaches in Opioid Development: Ensysce Biosciences and the $14 Million Grant for PF614-MPAR.
Disclaimer: The following article is intended for informational purposes only and should not be construed as medical advice or an endorsement of any specific product or company. All opinions are based on publicly available information and do not reflect the views of any organization or institution involved in the development or f…